We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Emergent Biosolutions, Horizon, Novavax, Celldex and Aileron Therapeutics
Read MoreHide Full Article
For Immediate Release
Chicago, IL – August 25, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Emergent Biosolutions Inc. (EBS - Free Report) , Horizon Therapeutics , Novavax, Inc. (NVAX - Free Report) , Celldex Therapeutics, Inc. (CLDX - Free Report) and Aileron Therapeutics, Inc. (ALRN - Free Report) .
Here are highlights from Monday’s Analyst Blog:
5 Biotech Stocks Up More Than 100% This Year So Far
The Zacks Medical-Biomedical and Genetics industry consists of several large as well as small pharma companies. The larger companies, which hold the majority of the industry’s market capitalization, have a strong portfolio of commercial drugs and pipeline candidates. These companies also boast a strong balance sheet and a steady stream of revenues.
However, the majority of the companies in the sector are small with a few to no marketed drugs. Most of these companies are in development-stage especially with focus on diseases, which are rare to treat or have significant unmet need like fatty liver, uncommon cancer indications and others.
Some of these clinical stage biotech companies are dependent on just one pipeline candidate. Consequently, the success or failure of their key pipeline candidates in clinical studies affects a stock’s price. These stocks are also affected by a partnership deal or the loss of one with a big pharma company as the latter provides significant funding for research.
The Zacks Medical-Biomedical and Genetics industry has risen 1.4% so far this year, outperforming the broader Medical market’s increase of 0.5%. Moreover, the Medical-Biomedical and Genetics industry has risen 26.5% since mid-March amid the coronavirus crisis.
The upside in biotech sector has been led by the small companies, primarily the ones developing a vaccine for coronavirus. Shares of some companies developing coronavirus vaccine candidates have witnessed sizable gains on hopes that a successful development will likely lead to significant amount of revenues amid the pandemic. Some among them are solely focused on developing the vaccine with no other pipeline candidates.
Moreover, biotechs developing a vaccine against COVID-19 are also attracting significant amount of funding from governments across the world and other public as well as private organizations to support development. Meanwhile, a few large-cap companies like Pfizer, Sanofi and Glaxo have also collaborated with small biotechs in search of a vaccine, which boosted their stock prices.
Please note that Moderna, Pfizer and, AstraZeneca are leading names involved in developing a vaccine. Emergent Biosolutions is one of the companies leading the race of companies providing manufacturing services to vaccine makers.
Apart from coronavirus-related developments, a few companies have surged on the back of encouraging progress with their pipeline candidates, especially for oncology indications.
Stocks That Outperformed
Here we have zeroed in on five biotech companies, which have risen more than 100% so far this year and witnessed positive earnings estimate revisions. These stocks either sport a Zacks Rank #1 (Strong Buy) or 2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Emergent Biosolutions Inc.
Emergent Biosolutions sports a Zacks Rank #1. The company surpassed earnings estimates in three of the last four reported quarters and missed the same once with the average beat being 127.41%. The Zacks Consensus Estimate for earnings has moved up 56.4% for 2020 in the past 30 days. Shares of the company have rallied 137.3% so far in 2020.
Horizon Therapeutics
Another Zacks Rank #1 company, Horizon Therapeutics surpassed earnings estimates in all the last four reported quarters with the average beat being 38.63%. The Zacks Consensus Estimate for earnings has moved north by 51.3% for 2020 in the past 30 days. Shares of the company have rallied 108.1% year to date.
Novavax, Inc.
Novavax is a Zacks Rank #2 company. The four-quarter average earnings beat is 13.8%. The Zacks Consensus Estimate for earnings has increased 34% for 2020 in the past 30 days. Shares of the company have rallied 3357.8% so far this year.
Celldex Therapeutics, Inc.
Celldex surpassed earnings estimates in two of the past four quarters with the average beat being 10.8%. The Zacks Consensus Estimate for loss has narrowed 42.7% for 2020 in the past 30 days. Shares of the company have rallied 392.8% year to date. The company carries a Zacks Rank #2.
Aileron Therapeutics, Inc.
Aileron carries a Zacks Rank #2. The Zacks Consensus Estimate for loss has narrowed 4.5% for 2020 in the past 30 days. Shares of the company have rallied 114.7% so far in 2020.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.3% per year.
These 7 were selected because of their superior potential for immediate breakout.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Emergent Biosolutions, Horizon, Novavax, Celldex and Aileron Therapeutics
For Immediate Release
Chicago, IL – August 25, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Emergent Biosolutions Inc. (EBS - Free Report) , Horizon Therapeutics , Novavax, Inc. (NVAX - Free Report) , Celldex Therapeutics, Inc. (CLDX - Free Report) and Aileron Therapeutics, Inc. (ALRN - Free Report) .
Here are highlights from Monday’s Analyst Blog:
5 Biotech Stocks Up More Than 100% This Year So Far
The Zacks Medical-Biomedical and Genetics industry consists of several large as well as small pharma companies. The larger companies, which hold the majority of the industry’s market capitalization, have a strong portfolio of commercial drugs and pipeline candidates. These companies also boast a strong balance sheet and a steady stream of revenues.
However, the majority of the companies in the sector are small with a few to no marketed drugs. Most of these companies are in development-stage especially with focus on diseases, which are rare to treat or have significant unmet need like fatty liver, uncommon cancer indications and others.
Some of these clinical stage biotech companies are dependent on just one pipeline candidate. Consequently, the success or failure of their key pipeline candidates in clinical studies affects a stock’s price. These stocks are also affected by a partnership deal or the loss of one with a big pharma company as the latter provides significant funding for research.
The Zacks Medical-Biomedical and Genetics industry has risen 1.4% so far this year, outperforming the broader Medical market’s increase of 0.5%. Moreover, the Medical-Biomedical and Genetics industry has risen 26.5% since mid-March amid the coronavirus crisis.
The upside in biotech sector has been led by the small companies, primarily the ones developing a vaccine for coronavirus. Shares of some companies developing coronavirus vaccine candidates have witnessed sizable gains on hopes that a successful development will likely lead to significant amount of revenues amid the pandemic. Some among them are solely focused on developing the vaccine with no other pipeline candidates.
Moreover, biotechs developing a vaccine against COVID-19 are also attracting significant amount of funding from governments across the world and other public as well as private organizations to support development. Meanwhile, a few large-cap companies like Pfizer, Sanofi and Glaxo have also collaborated with small biotechs in search of a vaccine, which boosted their stock prices.
Please note that Moderna, Pfizer and, AstraZeneca are leading names involved in developing a vaccine. Emergent Biosolutions is one of the companies leading the race of companies providing manufacturing services to vaccine makers.
Apart from coronavirus-related developments, a few companies have surged on the back of encouraging progress with their pipeline candidates, especially for oncology indications.
Stocks That Outperformed
Here we have zeroed in on five biotech companies, which have risen more than 100% so far this year and witnessed positive earnings estimate revisions. These stocks either sport a Zacks Rank #1 (Strong Buy) or 2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Emergent Biosolutions Inc.
Emergent Biosolutions sports a Zacks Rank #1. The company surpassed earnings estimates in three of the last four reported quarters and missed the same once with the average beat being 127.41%. The Zacks Consensus Estimate for earnings has moved up 56.4% for 2020 in the past 30 days. Shares of the company have rallied 137.3% so far in 2020.
Horizon Therapeutics
Another Zacks Rank #1 company, Horizon Therapeutics surpassed earnings estimates in all the last four reported quarters with the average beat being 38.63%. The Zacks Consensus Estimate for earnings has moved north by 51.3% for 2020 in the past 30 days. Shares of the company have rallied 108.1% year to date.
Novavax, Inc.
Novavax is a Zacks Rank #2 company. The four-quarter average earnings beat is 13.8%. The Zacks Consensus Estimate for earnings has increased 34% for 2020 in the past 30 days. Shares of the company have rallied 3357.8% so far this year.
Celldex Therapeutics, Inc.
Celldex surpassed earnings estimates in two of the past four quarters with the average beat being 10.8%. The Zacks Consensus Estimate for loss has narrowed 42.7% for 2020 in the past 30 days. Shares of the company have rallied 392.8% year to date. The company carries a Zacks Rank #2.
Aileron Therapeutics, Inc.
Aileron carries a Zacks Rank #2. The Zacks Consensus Estimate for loss has narrowed 4.5% for 2020 in the past 30 days. Shares of the company have rallied 114.7% so far in 2020.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.3% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>
Join us on Facbook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.